Is VRd induction suitable for patients with NDMM and renal impairment?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Sikander Ailawadhi, Mayo Clinic, Jacksonville, US. We asked: is induction therapy with bortezomib, lenalidomide, and dexamethasone (VRd) suitable for patients with newly diagnosed multiple myeloma (NDMM) and renal impairment?

Sikander Ailawadhi discusses data from the national Connect MM Registry, where patient data is recorded from a real-world setting. He describes the promising results and survival data of an observation study that assessed renal function in patients grouped by transplant eligibility status and renal function.